Related Experiment Videos
Neuroendocrine gastrointestinal tumours
1Department of Internal Medicine, University Hospital, Uppsala, Sweden.
Summary
Neuroendocrine tumors of the gut and pancreas present diagnostic and therapeutic challenges. While often slow-growing, liver metastases worsen prognosis, necessitating medical treatment when surgery isn't curative.
Area of Science:
- Gastroenterology
- Oncology
- Endocrinology
Background:
- Neuroendocrine gut and pancreatic tumors pose diagnostic and therapeutic challenges.
- While often slow-growing with a good prognosis, liver metastases significantly worsen outcomes.
- Many patients present with advanced disease, requiring medical management over surgical cure.
Purpose of the Study:
- To review current diagnostic and therapeutic strategies for neuroendocrine gut and pancreatic tumors.
- To highlight advancements in imaging and molecular diagnostics.
- To discuss the evolving role of surgery and medical treatments.
Main Methods:
- Histopathological diagnosis with silver stainings and immunohistochemistry (chromogranin A, synaptophysin).
- Plasma chromogranin A analysis for screening and adjunct diagnosis.
- Advanced imaging including somatostatin receptor scintigraphy (octreoscan) and endoscopic ultrasonography for staging and treatment guidance.
Main Results:
- Chromogranin A is elevated in 80%-100% of patients with verified neuroendocrine gastrointestinal tumors.
- Somatostatin receptor scintigraphy identifies somatostatin receptor subtype 2 binding in almost 80% of tumors, guiding somatostatin analogue therapy.
- Surgery, including debulking and bypassing, plays a crucial role even in advanced disease.
Conclusions:
- Accurate diagnosis relies on integrated histopathology, serological markers, and advanced imaging.
- Multimodal treatment involving surgery, chemotherapy, somatostatin analogues, and alpha-interferons is essential for disease control.
- Future individualized treatments will be based on tumor biology, including proliferation and molecular markers.